Search

Your search keyword '"Tanwandee, T."' showing total 82 results

Search Constraints

Start Over You searched for: Author "Tanwandee, T." Remove constraint Author: "Tanwandee, T." Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
82 results on '"Tanwandee, T."'

Search Results

1. Liver Dysfunction in Hyperthyroidism

2. Yellow Urticaria: A Systematic Review

3. Global multi-stakeholder endorsement of the MAFLD definition

4. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

5. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy

7. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

8. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

10. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.

11. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

12. Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.

13. Final results of ACHIEVE-2/3: Albinterferon alfa-2b plus ribavirin in treatment-naive patients with genotype 2/3 chronic hepatitis C.

19. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma

20. Global multi-stakeholder endorsement of the MAFLD definition

21. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study

22. Global multi-societies endorsement of the MAFLD definition.

23. A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis.

24. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.

25. Development and clinical validation of a novel algorithmic score (GAAD) for detecting HCC in prospective cohort studies.

26. Discovery of a haptoglobin glycopeptides biomarker panel for early diagnosis of hepatocellular carcinoma.

27. A Comparison of Clinical Manifestations and Outcomes between Acute Sporadic Hepatitis A and Hepatitis E Infections in Thailand.

28. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.

29. A Novel and Simplified Score for Determining Treatment Eligibility for Patients with Chronic Hepatitis B.

30. Prognostic Relevance of Metabolic Dysfunction-associated Steatohepatitis for Patients with Chronic Hepatitis B.

31. Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B.

32. Validation of prognostic scores predicting mortality in acute liver decompensation or acute-on-chronic liver failure: A Thailand multicenter study.

33. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.

34. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.

35. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.

36. Acute-on-chronic liver failure: Epidemiology, prognosis, and outcome of a multicenter study in Thai population.

37. Effect of a 12-week home-based exercise training program on aerobic capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a randomized controlled clinical trial.

38. Knowledge, attitude, and behaviors toward liver health and viral hepatitis-related liver diseases in Thailand.

40. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients.

41. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report.

42. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.

43. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries.

44. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.

45. Validation of the prognostic models in acute-on-chronic liver failure precipitated by hepatic and extrahepatic insults.

46. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study

47. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis.

48. Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infection.

49. Factors affecting mortality and resource use for hospitalized patients with cirrhosis: A population-based study.

50. Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study.

Catalog

Books, media, physical & digital resources